SOUTH SAN FRANCISCO, Calif.--()--Fluxion Biosciences, a privately held drug discovery tools and services company, announced today that it has launched the BioFlux EZ system. The BioFlux EZ addition completes the BioFlux family of products, and maintains the simplicity of operation and rapid experimental setup that are hallmarks of the entire product suite.
“The BioFlux EZ opens an introductory level option with an upgrade path that protects our customers’ investments, while maintaining the same high quality data and simplicity of operation our customers have come to expect from the BioFlux systems”
The BioFlux systems incorporate microfluidic designs into off-the-shelf consumables with temperature and gas controls that can sustain cell monolayers and a supporting extra-cellular matrix. The result is a physiologically relevant microenvironment that mimics the human vasculature and other organ systems where flow is present. This functionality enables live cell assays that require real-time, long term analysis of human cell lines under sensitive environmental conditions, and simplifies complex work flows.
Cell Biology researchers can now choose from a range of systems with an upgrade path to fully automated microscopy solutions, including a high quality, budget friendly system. “The BioFlux EZ opens an introductory level option with an upgrade path that protects our customers’ investments, while maintaining the same high quality data and simplicity of operation our customers have come to expect from the BioFlux systems,” said Jeff Jensen, President and CEO of Fluxion Biosciences.
Fluxion Biosciences products are available for direct purchase in North America and through the company’s extensive international distributor network. For more information about the BioFlux EZ and the complete product offerings, visit www.fluxionbio.com.
About Fluxion Biosciences
Fluxion Biosciences develops cellular analysis tools for use in critical applications in life sciences research and drug discovery. Fluxion’s technology facilitates the characterization of molecular and cellular mechanisms in physiologically relevant microenvironments. Fluxion helps to bridge the translational biology gap by bringing research data closer to patients and clinical trials. Our innovative systems for live cell analysis are enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests. For more information about Fluxion Biosciences, visit www.fluxionbio.com.